Martin Shkreli Violated Lifetime Ban From Drug Industry, U.S. Says
- Martin Shkreli allegedly violated his lifetime drug industry ban by publicly trading dozens of pharma stocks and yapping about it online.
- FTC and attorneys general from NY plus six other states filed a motion demanding he divest all pharma holdings and hand over profits.
- The 2022 ban stemmed from his sleazy Daraprim price hike scheme, which blocked generics and gouged patients for a life-saving med.
- FTC Commissioner Mark Meador calls it a 'deliberate pattern of defiance'—since when did Shkreli ever do anything subtle?
- His lawyers are mysteriously unavailable, and Shkreli can't be reached, probably because he's busy buying more shares in his own downfall.
Brief Summary
Martin Shkreli, the infamous 'Pharma Bro' who once jacked up a parasitic infection drug by 5,000%, is back in legal crosshairs for allegedly treating his lifetime industry ban like a parking ticket. The FTC and a posse of state attorneys general filed papers Tuesday claiming Shkreli 'repeatedly and flagrantly' traded dozens of pharma stocks and shared his brilliant industry takes online—all while the 2022 court order said, in no uncertain terms, 'stay out.' The feds want him to dump every pharma share he owns and cough up any cash made from these defiant trades, which would be a poetic twist for a man who once treated profiting off illness as a business model. The suit paints Shkreli as a man who learned nothing, because apparently a lifetime ban is just a suggestion when you're convinced you're the smartest guy in the room. His lawyers aren't commenting, and Shkreli's phone is conveniently dead—likely because it's on vibrate mode inside a wallet stuffed with dividend checks from his latest 'oops' investment.
Why This Matters
Why you should care: because Shkreli isn't just some meme villain—he's a cautionary tale about how the wealthy and connected can try to skate around rules with a wink and a smirk. If he gets away with this, it sends a message that court-ordered bans are just theater for the little people, while billionaires with fast Wi-Fi can trade their way back into the game. This case is also a direct hit to your wallet: the original Daraprim stunt meant patients paid hundreds for a drug that costs pennies to make, and his alleged new moves prove he's still gaming the system, just with a keyboard instead of a press release. Watch this one closely, because if the courts spank him hard enough, maybe the next Pharma Bro will think twice before treating the law like a suggestion box. And if they don't, well, enjoy your next prescription surcharge.